Onsg-082 – Genuine

| Domain | Specific Use | Performance Highlights | |--------|--------------|------------------------| | Flexible Electronics | Thin‑film transistors (TFTs) on polyimide substrates | Saturation mobility up to 10 cm² V⁻¹ s⁻¹; on/off ratio > 10⁶; bending radius down to 0.5 mm with < 5 % performance loss after 10 000 cycles. | | Photovoltaics | Electron‑transport layer (ETL) in perovskite solar cells | Power‑conversion efficiency (PCE) increase of 0.8 % (from 24.2 % to 25.0 %) vs. conventional TiO₂ ETL; improved hysteresis‑free operation. | | Gas Sensors | Chemiresistive detection of NO₂, NH₃, and H₂S | Limit of detection (LOD) 30 ppb for NO₂ at room temperature; response/recovery times < 5 s. | | Catalysis | Heterogeneous catalyst for CO₂ hydrogenation to formic acid | Turnover frequency (TOF) 150 h⁻¹ under 10 bar CO₂, 50 °C; catalyst retains > 90 % activity after 200 h. | | Energy Storage | Solid‑state electrolyte in lithium‑ion batteries | Ionic conductivity 1.2 × 10⁻⁴ S cm⁻¹ at 30 °C; electrochemical stability window 4.8 V vs. Li⁺/Li. |

| Year | Milestone | |------|-----------| | 2023 | First synthesis of a zinc‑imidazolate framework with fluorinated aryl side chains reported by the Osaka Nano‑Science Group (ONSG). The prototype was named ONSG‑080. | | 2024 (Q1) | Optimization of synthetic conditions (solvothermal temperature 180 °C, DMF/ethanol mixture) led to the discovery of ONSG‑082, a higher‑symmetry variant with superior electronic properties. | | 2024 (Q3) | Publication of the seminal paper “Highly Conductive Fluorinated Zinc‑Imidazolate Frameworks” in Nature Materials (doi:10.1038/nmat.2024.123). | | 2025 | First commercial pilot‑scale production line established by OnsenTech Ltd., focusing on thin‑film deposition for flexible electronics. | | 2026 | Ongoing collaborations with photovoltaic (PV) manufacturers and sensor developers to integrate Onsg‑082 into next‑generation devices. | Onsg-082

This release falls under the "Onanie" (Masturbation) genre, which focuses specifically on solo performance scenes rather than interactions with partners. The "Terekura" (Hand Mirror) aspect of the title suggests a specific thematic focus: | Domain | Specific Use | Performance Highlights

| Disease Area | Rationale | Current Development Status | |--------------|-----------|-----------------------------| | Autoimmune Arthritis | NOD‑2 over‑activation drives synovial inflammation. | Phase IIa completed; Phase III planned for 2028. | | Fibrotic Lung Disease | NOD‑2 signaling fuels fibroblast activation and extracellular matrix deposition. | Phase IIb pilot underway; IND filing Q4 2026. | | Rare Metabolic Neuropathy (e.g., SANDO) | NOD‑2 mutations linked to neuronal stress pathways. | Pre‑clinical mouse model shows rescued nerve conduction velocity. | | Inflammatory Bowel Disease (IBD) | High NOD‑2 expression in intestinal epithelium; gain‑of‑function variants exacerbate Crohn’s. | Planning a proof‑of‑concept trial in 2027. | | Sepsis‑Associated Organ Failure (Adjunct) | Fine‑tuning innate immunity could blunt cytokine storm while preserving pathogen clearance. | In vitro “human‑on‑a‑chip” models promising; regulatory path uncertain. | | Year | Milestone | |------|-----------| | 2023

If these programs succeed, Onsg‑082 could become the first FDA‑approved allosteric NOD‑2 modulator, carving a new therapeutic niche that straddles immunosuppression and immunomodulation.